Trimi’s public pricing explanation supplies a detail that many monthly-looking offers leave unclear: its $99 semaglutide figure is an annual-plan equivalent, with $1,188 due upfront for a twelve-month commitment. The month-to-month price is separately listed as $175. These are different purchase models, not interchangeable ways to quote one payment.
The same distinction applies to tirzepatide, advertised at $125 per month on an annual plan billed $1,500 upfront, or $235 month to month. This review keeps that financial clarity alongside the prescription, compounded-product and outcome limitations.
The annual equivalent is not a monthly charge
Trimi’s answers page states the total upfront amounts and describes no membership, enrollment or shipping fee within those offers. That makes the included-cost presentation relatively concrete. A reader can compare the full commitment rather than assuming the smallest monthly-looking figure is what leaves the account each month.
A year paid upfront also creates a different flexibility question from a month-to-month plan. The published amounts do not by themselves settle every cancellation or unused-term refund circumstance. The renewal guide makes those financial questions visible without assuming the annual offer is always better value.
The price includes a conditional clinical pathway
Trimi describes licensed provider review, pharmacy compounding, supplies and shipping within the price. It names Arora Health as its clinical network and says each prescription is reviewed by a licensed US provider. The actual medication still depends on that professional decision.
The page advertises an automatic refund when its medical team does not approve treatment. That is a specific nonapproval circumstance, distinct from the separate money-back promise connected to weight change. Neither description amounts to a personal eligibility assessment carried out by this publication.
Trial references do not become Trimi outcomes
The homepage names STEP-1, SURMOUNT-1 and SELECT and explicitly says the figures come from active-ingredient trials rather than guaranteeing individual results. That qualification is essential. These are not observed results from a Trimi patient cohort or a study of every compounded prescription it dispenses.
Trimi also states that compounded preparations are not FDA-approved as drugs. A named ingredient study, clinical network and pharmacy process have separate roles. The treatment guide explains why those features do not transfer a branded medicine’s approval to a compounded finished preparation.
The useful comparison is both financial and clinical
Trimi’s strongest public feature is the explicit upfront-versus-monthly distinction. The open question concerns the complete selected agreement, including continuing terms and how any refund promise works. This review did not purchase an annual plan, authenticate a pharmacy or measure a treatment outcome.
The Fridays review follows a four-month membership promotion, while Henry describes longer-plan balance qualifications. The cost guide connects those commitments. It does not treat an annual equivalent as proof of affordability or suitability for every reader.
Compare another model
Embody · CoreAge Rx · Noom Med · Ro
The invoice guide and product-status guide explain the distinctions behind these entries.
Documents used
Official public information reviewed October 1, 2026. Advertising describes an offer; it is not independent verification of treatment outcomes.